{"organizations": [], "uuid": "6d623a73ded3428fe6b9dd63ab80c89195e8f118", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-reports-p/brief-protalix-biotherapeutics-reports-positive-interim-data-from-phase-ii-clinical-trial-of-oprx-106-idUSASB0BZEC", "country": "US", "domain_rank": 408, "title": "BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T14:11:00.000+02:00", "replies_count": 0, "uuid": "6d623a73ded3428fe6b9dd63ab80c89195e8f118"}, "author": "", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-reports-p/brief-protalix-biotherapeutics-reports-positive-interim-data-from-phase-ii-clinical-trial-of-oprx-106-idUSASB0BZEC", "ord_in_thread": 0, "title": "BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-protalix biotherapeutics reports positive interim data", "sentiment": "negative"}, {"name": "protalix biotherapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 12 PM / Updated 10 minutes ago BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106 Reuters Staff 1 Min Read \nJan 2 (Reuters) - Protalix Biotherapeutics Inc: \n* PROTALIX BIOTHERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS \n* PROTALIX BIOTHERAPEUTICS - ‍TREATMENT WAS WELL TOLERATED AND MAJORITY OF ADVERSE EVENTS HAVE BEEN MILD TO MODERATE AND TRANSIENT IN NATURE IN STUDY​ \n* PROTALIX BIOTHERAPEUTICS - EXPECTS TO REPORT FULL RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 BY END OF Q1 2018  ", "external_links": [], "published": "2018-01-02T14:11:00.000+02:00", "crawled": "2018-01-02T14:32:26.031+02:00", "highlightTitle": ""}